Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.

Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.